Low-grade serous ovarian cancer
Prepared with OnCo (onco.cc/prep/low-grade-serous-ovarian-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
15 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example KRAS, BRAF and NRAS mutations, Oestrogen and progesterone receptor expression, Wild-type TP53, CA-125), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (first line), which of the standard options do you recommend and why?
- 6.Am I a candidate for Carboplatin, Paclitaxel / nab-paclitaxel, Letrozole (and other aromatase inhibitors), and what side effects should I expect?
- 7.For my situation (recurrent disease), which of the standard options do you recommend and why?
- 8.Am I a candidate for Trametinib, Avutometinib + defactinib, Letrozole (and other aromatase inhibitors), and what side effects should I expect?
- 9.For my situation (maintenance), which of the standard options do you recommend and why?
- 10.Am I a candidate for Letrozole (and other aromatase inhibitors), and what side effects should I expect?
- 11.Are there clinical trials I could join, for example of Avutometinib + defactinib, Trametinib?
- 12.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 13.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
- 14.I read that “Whether first-line chemotherapy adds anything to surgery and hormone therapy”. How does that affect my plan?
- 15.I read that “Options for MAPK wild-type tumours”. How does that affect my plan?
Tests and results to bring
Biomarker results to ask for: KRAS, BRAF and NRAS mutations, Oestrogen and progesterone receptor expression, Wild-type TP53 (distinguishes it from high-grade), CA-125 (less reliable than in high-grade disease).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- First line: Complete cytoreductive surgery; carboplatin-paclitaxel followed by letrozole maintenance, or letrozole alone in selected patients. (Carboplatin, Paclitaxel / nab-paclitaxel, Letrozole (and other aromatase inhibitors))
- Recurrent disease: Trametinib (GOG 281) or avutometinib plus defactinib for KRAS-mutant tumours; aromatase inhibitors; secondary surgery where complete resection is possible. (Trametinib, Avutometinib + defactinib, Letrozole (and other aromatase inhibitors))
- Maintenance: Letrozole after first-line treatment, continued for years while tolerated. (Letrozole (and other aromatase inhibitors))
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.